Seegene has received an Emergency Use Authorization (EUA) for COVID-19 diagnostic kit (Allplex™ 2019-nCoV Assay) from the Canadian ministry of health (Health Canada) on April 9^th.

Many countries have recognized the importance of test to identify infected people rapidly as a way to reduce COVID-19 infection spread. Although the Canadian government has implemented preventive measures against infection such as social distancing, etc. to respond to COVID-19, there are currently more than 20,000 confirmed patients.

In Canada, Seegene has secured high credibility and strong customer relationship through their excellent performances of respiratory infection related virus screening products they have been used. As a result, it is expected that medical institutions where have been using Seegene’s respiratory test panels will be able to accept this new COVID-19 test kit and start large volume of testing promptly.

Especially, the product assessment has been completed by the major medical institutions in the Province of Ontario which is the most densely populated region in Canada so that the mass testing will be performed soon. Moreover, last-minute preparations for COVID-19 test are underway in major hospitals in the Province of Quebec where the COVID-19 prevalence is highest in Canada.

Meanwhile, Seegene’s COVID-19 diagnostic product has marked of in vitro diagnostic device in Europe (CE-IVD) on February 13^th, and since then, it has  been obtained official approvals from Peru, Malaysia, Philippines, Ecuador, Columbia, Thailand, and Australia. It also has been approved for emergency use in India, Singapore, and Kazakhstan as well as Canada, and now they are currently supplying  to a total of 54 countries.